Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asx piq

  • Home
  •  
  • asx piq



  • Most Read
  • Latest Comments
  • Proteomics International to collaborate on world first blood test for endometriosis
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Proteomics International to collaborate on world first blood test for endometriosis
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Proteomics signs deal with Omics Global Solutions to provide Chile with early diabetic kidney disease detection
    Proteomics signs deal with Omics Global Solutions to provide Chile with early diabetic kidney disease detection
    • News

  • Proteomics’ early detection test for endometriosis potentially a game changer
    Proteomics’ early detection test for endometriosis potentially a game changer
    • News

  • Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice
    Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice
    • News

  • Predictive test for diabetic kidney disease receives new patent
    Predictive test for diabetic kidney disease receives new patent
    • News

  • Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test
    Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test
    • News

  • Proteomics International to collaborate on world first blood test for endometriosis
    • News

    Proteomics International to collaborate on world first blood test for endometriosis

    One in nine Australian women will suffer from endometriosis, a debilitating, chronic menstrual health disorder resulting in serious pain, fertility issues and reduced quality of life. The disease occurs when tissue similar to that within the lining of the uterus grows outside of the uterus in other areas of the body, commonly around the reproductive

    Read More
    Public
  • Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
    • News

    Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device

    Australian medtech developer Proteomics International Laboratories (PILL, ASX: PIQ) has reached a landmark milestone having secured CE Mark certification for commericalisation of their in vitro diagnostic medical device in Europe, which can predict the early onset of diabetic kidney disease. The device, PromarkerD, takes a blood test which then creates a unique protein fingerprint which

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.